vomiting on semaglutide exposure and nausea. Data show the proportion of Ozempic & the Gut: What

Cleo Ryals of the University of North Carolina at Chapel Hill also presented at the 2025 SABCS indicated there may be a connection between the use of GLP-1 agonists and reduced circulating tumor activity, suggesting that these medications may have benefits for patients with breast cancer beyond weight loss

Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations

Additionally, there is an overexpression of inflammatory mediators such as iNOS, Cox-2, and IL-17 in chloasma (151)

A 2023 study 24 showed that vitamin D may help enhance GLP-1 levels by improving the gut microbiome